Trial Profile
Pharmaco Kinetic and Pharmacokinetic-Pharmacodynamic Variability of Infliximab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms FAKIR
- 23 Feb 2010 Actual end date (November 2009) added as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 30 Jan 2010 Actual number of patients (84) added as reported by ClinicalTrials.gov record.